Sanofi, Qfitlia, Fitusiran, Haemophilia A, Haemophilia B, CDSCO Approval, RNA Interference, Antithrombin-Lowering Therapy, Rare Diseases, Bleeding Prevention, Phase 3 Clinical Trials

Mumbai, India, October 21, 2026 Sanofi has received marketing authorisation in India for Qfitlia® (fitusiran), an innovative antithrombin-lowering therapy...